Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Moodys
Dow
Boehringer Ingelheim
McKinsey

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR ENCORAFENIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Encorafenib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01777776 ↗ Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Terminated Array BioPharma Phase 1/Phase 2 2013-07-01 To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
NCT01820364 ↗ LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Terminated Array BioPharma Phase 2 2013-11-01 The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.
NCT02109653 ↗ Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC Withdrawn Array BioPharma Phase 2 2015-06-01 This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
NCT02109653 ↗ Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC Withdrawn Array Biopharma, now a wholly owned subsidiary of Pfizer Phase 2 2015-06-01 This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
NCT02263898 ↗ Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn National Cancer Institute (NCI) Phase 2 2015-01-01 This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time when tumors become resistant to the drugs.
NCT02263898 ↗ Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn Jonsson Comprehensive Cancer Center Phase 2 2015-01-01 This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time when tumors become resistant to the drugs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Encorafenib

Condition Name

Condition Name for Encorafenib
Intervention Trials
Melanoma 10
Metastatic Melanoma 8
BRAF V600E 5
BRAF V600 Mutation 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Encorafenib
Intervention Trials
Melanoma 25
Colorectal Neoplasms 13
Neoplasms 7
Brain Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Encorafenib

Trials by Country

Trials by Country for Encorafenib
Location Trials
United States 164
China 41
Italy 28
Japan 25
Spain 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Encorafenib
Location Trials
California 14
Texas 13
Tennessee 11
New York 10
Maryland 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Encorafenib

Clinical Trial Phase

Clinical Trial Phase for Encorafenib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2 30
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Encorafenib
Clinical Trial Phase Trials
Recruiting 30
Not yet recruiting 16
Active, not recruiting 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Encorafenib

Sponsor Name

Sponsor Name for Encorafenib
Sponsor Trials
Pfizer 17
Array BioPharma 13
National Cancer Institute (NCI) 12
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Encorafenib
Sponsor Trials
Industry 70
Other 47
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
Merck
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.